Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
InnoCare Pharma Ltd. ( (HK:9969) ) has provided an update.
InnoCare Pharma Ltd. has received approval from the National Medical Products Administration in China to conduct a Phase III clinical trial of ICP-248 (Mesutoclax) in combination with Orelabrutinib. This combination, aimed at treating chronic lymphocytic leukemia/small lymphocytic lymphoma, has shown promising efficacy and safety in previous trials. The advancement is part of InnoCare’s strategic efforts to provide effective treatment options for CLL/SLL patients and strengthen its position in the hemato-oncology market.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. operates in the pharmaceutical industry, focusing on developing innovative treatments for hematologic malignancies. The company specializes in B-cell lymphoma-2 inhibitors and is actively advancing its hemato-oncology pipeline, with a significant market focus in China and globally.
YTD Price Performance: 6.86%
Average Trading Volume: 4,187,168
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$9.79B
Learn more about 9969 stock on TipRanks’ Stock Analysis page.
